title: Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study.
abstract: OBJECTIVE
  The purpose of this study was to compare the gastric acid inhibitory ability of increasing doses of intravenous (i.i.) pantoprazole with that of i.v. famotidine and placebo. Pentagastrin was infused continuously in healthy subjects as a model for patients with Zollinger-Ellison syndrome.
  
  
  METHODS
  Pentagastrin (1 microg/kg/h) was infused to stimulate maximum acid output in 39 subjects over a 25-h period. After 60 min of pentagastrin infusion, subjects received a single dose of i.v. pantoprazole (20, 40, 80, or 120 mg), i.v. famotidine (20 mg), or saline placebo. The variables measured were onset of response (time until acid output fell to < 10 mEq/h), duration of response (time acid output remained < 10 mEq/h), and cumulative acid output over 24 h.
  
  
  RESULTS
  All doses of i.v. pantoprazole produced a dose-dependent suppression of acid output to < 10 mEq/h. Single i.v. doses of pantoprazole, 80 and 120 mg, suppressed acid output by > 90% in all subjects for < or = 21 h and had an onset of action of < 1 h.
  
  
  CONCLUSIONS
  Intravenous pantoprazole has a rapid onset and a clear dose-related effect, with a significantly longer duration of action than that of i.v. famotidine.
authors.affiliation: CURE Digestive Diseases Research Center, West LA VA Medical Center, University of California, Los Angeles 90073, USA.
authors.forename: J R
authors.initials: JR
authors.lastname: Pisegna
authors.forename: P
authors.initials: P
authors.lastname: Martin
authors.forename: W
authors.initials: W
authors.lastname: McKeand
authors.forename: G
authors.initials: G
authors.lastname: Ohning
authors.forename: J H
authors.initials: JH
authors.lastname: Walsh
authors.forename: J
authors.initials: J
authors.lastname: Paul
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D015738:Famotidine / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives; D000077402:Pantoprazole; D010418:Pentagastrin / Q000494:pharmacology*; D054328:Proton Pump Inhibitors; D013454:Sulfoxides / Q000008:administration & dosage / Q000494:pharmacology*; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D054328:Proton Pump Inhibitors; D013454:Sulfoxides; D015738:Famotidine; D000077402:Pantoprazole; D010418:Pentagastrin; D009853:Omeprazole